[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA39819A - Méthodes et compositions d'immunomodulation - Google Patents

Méthodes et compositions d'immunomodulation

Info

Publication number
MA39819A
MA39819A MA039819A MA39819A MA39819A MA 39819 A MA39819 A MA 39819A MA 039819 A MA039819 A MA 039819A MA 39819 A MA39819 A MA 39819A MA 39819 A MA39819 A MA 39819A
Authority
MA
Morocco
Prior art keywords
immunomodulation
compositions
methods
cells containing
exogenous antigen
Prior art date
Application number
MA039819A
Other languages
English (en)
Inventor
Noubar B Afeyan
Avak Kahvejian
Jordi Mata-Fink
John Round
Original Assignee
Rubius Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2014/065304 external-priority patent/WO2015073587A2/fr
Application filed by Rubius Therapeutics Inc filed Critical Rubius Therapeutics Inc
Publication of MA39819A publication Critical patent/MA39819A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0644—Platelets; Megakaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)

Abstract

L'invention concerne des cellules contenant un antigène exogène et les utilisations de celles-ci.
MA039819A 2014-04-01 2015-03-13 Méthodes et compositions d'immunomodulation MA39819A (fr)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201461973764P 2014-04-01 2014-04-01
US201461973763P 2014-04-01 2014-04-01
US201461991319P 2014-05-09 2014-05-09
US201462006828P 2014-06-02 2014-06-02
US201462006825P 2014-06-02 2014-06-02
US201462006832P 2014-06-02 2014-06-02
US201462006829P 2014-06-02 2014-06-02
US201462025367P 2014-07-16 2014-07-16
US201462059100P 2014-10-02 2014-10-02
PCT/US2014/065304 WO2015073587A2 (fr) 2013-11-18 2014-11-12 Complexes membrane synthétique- récepteur

Publications (1)

Publication Number Publication Date
MA39819A true MA39819A (fr) 2017-02-08

Family

ID=54241093

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039819A MA39819A (fr) 2014-04-01 2015-03-13 Méthodes et compositions d'immunomodulation

Country Status (18)

Country Link
US (4) US10869898B2 (fr)
EP (2) EP3125927B1 (fr)
JP (4) JP6735233B2 (fr)
KR (2) KR20220150986A (fr)
CN (1) CN106456744A (fr)
AU (3) AU2015241422B2 (fr)
BR (1) BR112016022814A8 (fr)
CA (1) CA2944492A1 (fr)
DK (1) DK3125927T3 (fr)
ES (1) ES2865825T3 (fr)
HU (1) HUE054471T2 (fr)
IL (3) IL248143B (fr)
MA (1) MA39819A (fr)
MX (1) MX2020000621A (fr)
PL (1) PL3125927T3 (fr)
PT (1) PT3125927T (fr)
RU (2) RU2736495C2 (fr)
WO (1) WO2015153102A1 (fr)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CN108117586A (zh) 2010-08-10 2018-06-05 洛桑聚合联合学院 红细胞结合性治疗剂
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
AU2012326203B2 (en) 2011-10-17 2017-11-30 Massachusetts Institute Of Technology Intracellular delivery
US10689609B2 (en) 2012-03-15 2020-06-23 Flodesign Sonics, Inc. Acoustic bioreactor processes
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10322949B2 (en) 2012-03-15 2019-06-18 Flodesign Sonics, Inc. Transducer and reflector configurations for an acoustophoretic device
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9745548B2 (en) 2012-03-15 2017-08-29 Flodesign Sonics, Inc. Acoustic perfusion devices
US9752113B2 (en) 2012-03-15 2017-09-05 Flodesign Sonics, Inc. Acoustic perfusion devices
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10737953B2 (en) 2012-04-20 2020-08-11 Flodesign Sonics, Inc. Acoustophoretic method for use in bioreactors
ES2865107T3 (es) 2013-08-16 2021-10-15 Massachusetts Inst Technology Administración selectiva de material a células
US9745569B2 (en) 2013-09-13 2017-08-29 Flodesign Sonics, Inc. System for generating high concentration factors for low cell density suspensions
AU2014348683B2 (en) 2013-11-18 2020-11-05 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
CA2935960C (fr) 2014-01-08 2023-01-10 Bart Lipkens Dispositif d'acoustophorese avec double chambre acoustophoretique
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
WO2015140648A2 (fr) 2014-02-21 2015-09-24 Ecole Polytecnique Federale De Lausanne (Epfl) Epfl-Tto Agents thérapeutiques de glycociblage
AU2015241422B2 (en) 2014-04-01 2020-12-03 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
US9744483B2 (en) 2014-07-02 2017-08-29 Flodesign Sonics, Inc. Large scale acoustic separation device
RU2020139190A (ru) 2014-10-31 2021-01-26 Массачусетс Инститьют Оф Текнолоджи Доставка биомолекул в клетки иммунной системы
US10526573B2 (en) 2014-11-14 2020-01-07 Massachusetts Institute Of Technology Disruption and field enabled delivery of compounds and compositions into cells
AU2016206870B2 (en) 2015-01-12 2022-02-17 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11420136B2 (en) 2016-10-19 2022-08-23 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
JP6925984B2 (ja) 2015-07-09 2021-08-25 マサチューセッツ インスティテュート オブ テクノロジー 無核細胞への物質の送達
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11613759B2 (en) 2015-09-04 2023-03-28 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
CN108135940B (zh) 2015-10-14 2022-04-15 株式会社美加细胞 纯化血小板的制造方法
BR112018013728A2 (pt) 2016-01-11 2018-12-18 Rubius Therapeutics Inc composições e métodos relacionados a sistemas celulares terapêuticos multimodais para indicações imunitárias
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
BR112019000195A2 (pt) * 2016-07-07 2019-04-24 Rubius Therapeutics, Inc. composições e métodos relacionados a sistemas celulares terapêuticos que expressam rna exógeno
EP3506919A4 (fr) * 2016-09-02 2020-04-15 The Board of Trustees of the University of Illinois Peptide dérivé de kif13b et procédé d'inhibition de l'angiogenèse
WO2018102740A1 (fr) * 2016-12-02 2018-06-07 Rubius Therapeutics, Inc. Compositions et méthodes se rapportant à des systèmes cellulaires destinés à pénétrer dans des tumeurs solides
WO2018144966A1 (fr) * 2017-02-06 2018-08-09 The Board Of Trustees Of The Leland Stanford Junior University Procédés de bioconjugaison pour une administration thérapeutique in situ ciblée
MX2019009839A (es) 2017-02-17 2019-10-22 Rubius Therapeutics Inc Celulas eritroides funcionalizadas.
EP3595681A4 (fr) * 2017-03-16 2020-12-16 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Immunothérapie à base de cellules pouvant être greffées pour l'administration sur une longue période de protéines thérapeutiques
WO2018232176A1 (fr) 2017-06-16 2018-12-20 The University Of Chicago Compositions et procédés d'induction d'une tolérance immunitaire
EP3654991A1 (fr) 2017-07-19 2020-05-27 Rubius Therapeutics, Inc. Compositions et méthodes associées à des systèmes cellulaires thérapeutiques multimodaux pour le traitement d'une maladie infectieuse
US20200172867A1 (en) 2017-07-19 2020-06-04 Rubius Therapeutics, Inc. Compositions and methods related to multimodal therapeutic cell systems for cardiometabolic disease
EP3661966A4 (fr) * 2017-07-31 2021-07-21 Tizona Therapeutics Anticorps anti-cd39, compositions comprenant des anticorps anti-cd39 et méthodes d'utilisation d'anticorps anti-cd39
EP3664830A4 (fr) * 2017-08-07 2020-07-01 The Regents of the University of California Plate-forme de génération d'agents thérapeutiques cellulaires sans risque
US10960071B2 (en) 2017-08-07 2021-03-30 The Regents Of The University Of California Platform for generating safe cell therapeutics
EP3672602A1 (fr) 2017-08-22 2020-07-01 Rubius Therapeutics, Inc. Procédés et compositions de nanoparticules lipidiques destinés à la production de cellules érythroïdes modifiées
CN107510839A (zh) * 2017-08-31 2017-12-26 广东颜值科技有限公司 一种免疫调节剂及其制备方法和应用
US20190160102A1 (en) 2017-11-03 2019-05-30 Rubius Therapeutics, Inc. Compositions and methods related to therapeutic cell systems for tumor growth inhibition
EP3725092A4 (fr) 2017-12-14 2021-09-22 FloDesign Sonics, Inc. Circuit d'excitation et circuit de commande de transducteur acoustique
AU2018389346B2 (en) * 2017-12-23 2022-08-25 Rubius Therapeutics, Inc. Artificial antigen presenting cells and methods of use
US20190201548A1 (en) 2017-12-29 2019-07-04 Rubius Therapeutics, Inc. Gene editing and targeted transcriptional modulation for engineering erythroid cells
MX2020007071A (es) 2018-01-05 2020-11-11 Platelet Biogenesis Inc Composiciones y metodos para producir megacariocitos.
WO2019140116A2 (fr) 2018-01-10 2019-07-18 Rubius Therapeutics, Inc. Arn amplifiables pour systèmes cellulaires thérapeutiques
WO2019165183A1 (fr) 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions et méthodes de traitement de l'encéphalopathie mitochondriale neurogastro-intestinale
SG11202008261WA (en) 2018-03-08 2020-09-29 Rubius Therapeutics Inc Therapeutic cell systems and methods for treating cancer and infectious diseases
US20190309269A1 (en) 2018-03-20 2019-10-10 Rubius Therapeutics, Inc. Therapeutic cell systems and methods for treating hyperuricemia and gout
US20190309271A1 (en) 2018-03-20 2019-10-10 Rubius Therapeutics, Inc. Therapeutic cell systems and methods for treating homocystinuria
BR112020022405A2 (pt) * 2018-05-16 2021-04-13 Csl Limited Variantes de receptor de complemento solúvel tipo 1 e usos dos mesmos
JP2021529770A (ja) * 2018-06-29 2021-11-04 プレートレット バイオジェネシス， インコーポレイテッド 薬物送達のための組成物およびその使用方法
US20200172597A1 (en) 2018-12-03 2020-06-04 Rubius Therapeutics, Inc. Artificial antigen presenting cells including hla-e and hla-g molecules and methods of use
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
MA54468A (fr) * 2018-12-11 2022-04-13 Q32 Bio Inc Constructions de protéines de fusion pour une maladie associée au complément
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
AU2020209941A1 (en) 2019-01-18 2021-07-22 Flagship Pioneering, Inc. TREM compositions and uses thereof
CN109810992A (zh) * 2019-02-01 2019-05-28 天津师范大学 一种编码牙鲆胞外ATP水解酶CD39的cDNA全长序列及其应用
WO2020172472A1 (fr) 2019-02-20 2020-08-27 Rubius Therapeutics, Inc. Cellules érythroïdes modifiées comprenant des polypeptides de présentation d'antigène chargeables et procédés d'utilisation
CA3128626A1 (fr) 2019-03-04 2020-09-10 Flagship Pioneering Innovations Vi, Llc Polyribonucleotides circulaires et compositions pharmaceutiques associees
KR20210142678A (ko) 2019-03-25 2021-11-25 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 변형된 원형 폴리리보뉴클레오티드를 포함하는 조성물 및 그의 용도
US20200338129A1 (en) * 2019-04-26 2020-10-29 Rubius Therapeutics, Inc. Compositions including enucleated erythroid cells
CN110244053B (zh) * 2019-05-09 2022-03-11 北京大学第三医院（北京大学第三临床医学院） 用于诊断狼疮肾炎并肺动脉高压疾病的分子标志物及其用途
EP3976782A1 (fr) 2019-05-31 2022-04-06 Flagship Pioneering, Inc. Utilisations de compositions trem pour moduler des ensembles d'arnt
CN110215737B (zh) * 2019-06-13 2021-07-02 厦门华厦学院 一种基于石墨烯-纳米金复合界面超高负载核酸适配体的亲和整体柱及其制备方法
EP3983539A1 (fr) 2019-06-14 2022-04-20 Flagship Pioneering Innovations VI, LLC Arn circulaires pour thérapie cellulaire
EP3986469A1 (fr) 2019-06-19 2022-04-27 Flagship Pioneering Innovations VI, LLC Compositions comprenant des polyribonucléotides circulaires pour la modulation de protéine et leurs utilisations
BR112021026292A2 (pt) 2019-06-26 2022-05-31 Univ Colorado Regents Cistationina beta sintase peguilada para terapia enzimática para tratamento de homocistinúria
EP4025048A2 (fr) 2019-09-05 2022-07-13 Hemanext Inc. Procédés de conservation d'érythrocytes réactifs à l'aide de monoxyde de carbone
EP4055169A1 (fr) 2019-11-04 2022-09-14 Flagship Pioneering, Inc. Procédés de modification d'une séquence d'acide nucléique
WO2021092064A1 (fr) 2019-11-04 2021-05-14 Flagship Pioneering, Inc. Compositions trem pour des codons con-rare et utilisations associées
WO2021096972A1 (fr) * 2019-11-11 2021-05-20 The Regents Of The University Of California Nanoparticules polymères ciblant des cellules endothéliales sinusoïdales du foie pour induire une tolérance immunitaire spécifique à l'antigène
EP4061403A4 (fr) * 2019-11-19 2023-12-27 Spark Therapeutics, Inc. Tolérance immunitaire induite par des protéines sécrétables et traitement de maladies et de troubles auto-immuns, allergiques et autres
CN115279415A (zh) 2020-01-29 2022-11-01 旗舰创业创新第六有限责任公司 用于蛋白调节的包含线性多核糖核苷酸的组合物及其用途
US20230104113A1 (en) 2020-01-29 2023-04-06 Flagship Pioneering Innovations Vi, Llc Delivery of compositions comprising circular polyribonucleotides
TW202142689A (zh) 2020-01-29 2021-11-16 美商旗艦先鋒創新有限責任公司 用於轉譯之組合物及其使用方法
JP2023513263A (ja) 2020-02-10 2023-03-30 ルビウス セラピューティクス， インコーポレイテッド Ｈｌａ－ｇポリペプチドを含む操作された赤血球系細胞およびその使用方法
US20230210978A1 (en) * 2020-04-02 2023-07-06 Francois Binette A universal adoptive immunotherapy approach to treat covid-19 and future emerging infectious diseases
IL298363A (en) 2020-05-20 2023-01-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and uses thereof
US20230203192A1 (en) 2020-05-20 2023-06-29 Flagship Pioneering, Inc. Compositions and methods for producing human polyclonal antibodies
JP2023526422A (ja) 2020-05-20 2023-06-21 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー コロナウイルス抗原組成物及びそれらの使用
CA3182026A1 (fr) 2020-05-29 2021-12-02 Flagship Pioneering Innovations Vi, Llc. Compositions a base de trem et procedes associes
CN116018405A (zh) 2020-05-29 2023-04-25 旗舰先锋创新Vi有限责任公司 Trem组合物及其相关方法
RU2743363C1 (ru) * 2020-06-03 2021-02-17 федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный аграрный университет" Способ тестирования иммунологической толерантности у животных
EP4165181A2 (fr) 2020-06-14 2023-04-19 Vertex Pharmaceuticals Incorporated Compositions et procédés associés au facteur i du complément
EP4167984A1 (fr) 2020-06-23 2023-04-26 Flagship Pioneering, Inc. Composés antiviraux et leurs procédés d'utilisation
WO2022005996A1 (fr) * 2020-06-29 2022-01-06 Memorial Sloan Kettering Cancer Center SYSTÈMES POUR SURVEILLER IN VIVO DES CELLULES IMMUNITAIRES CHEZ DES PATIENTS SUBISSANT UNE IMMUNOTHÉRAPIE CELLULAIRE<i />
WO2022005991A1 (fr) * 2020-06-29 2022-01-06 Memorial Sloan Kettering Cancer Center Plate-forme pour évaluer in vivo et in vitro la capture d'haptène dans un système lié à une cellule
US20230349902A1 (en) * 2020-07-27 2023-11-02 Commissariat A L'energie Atomique Et Aux Energies Alternatives Novel t cells and the uses thereof
CN112156111B (zh) * 2020-08-31 2022-10-18 中南大学湘雅三医院 脐血血小板线粒体在制备治疗自身免疫疾病药物中的应用
TW202218669A (zh) 2020-09-03 2022-05-16 美商旗艦先鋒創新有限責任公司 免疫原性組成物及其用途
CN112285361B (zh) * 2020-09-27 2023-12-05 中国人民解放军空军军医大学 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂
CN116782827A (zh) * 2020-11-30 2023-09-19 明德拉公司 微针装置和方法以及皮肤病状测定
CN112544989A (zh) * 2020-12-18 2021-03-26 完美（广东）日用品有限公司 一种具有肌肉保护作用的组合物
EP4267732A1 (fr) 2020-12-23 2023-11-01 Flagship Pioneering Innovations VI, LLC Compositions de molécules effectrices à base d'arnt (trem) modifiées et leurs utilisations
CA3203709A1 (fr) * 2020-12-29 2022-07-07 Sqz Biotechnologies Company Formulations d'activation de porteurs d'antigene
RU2766780C1 (ru) * 2020-12-30 2022-03-15 федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный аграрный университет" Способ определения антигенной нагрузки животных
TW202241470A (zh) 2021-01-08 2022-11-01 美商盧比亞斯治療公司 治療人類個體腫瘤之方法
WO2022150569A1 (fr) 2021-01-08 2022-07-14 Rubius Therapeutics, Inc. Méthodes d'augmentation de lymphocytes nkp30-positifs chez un sujet et leurs utilisations
WO2022197548A1 (fr) 2021-03-14 2022-09-22 Rubius Therapeutics, Inc. Méthodes d'augmentation des lymphocytes nkg2d-positifs chez un sujet et utilisations correspondantes
EP4313109A1 (fr) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Polypeptides de thanotransmission et leur utilisation dans le traitement du cancer
TW202317179A (zh) 2021-06-03 2023-05-01 美商盧比亞斯治療公司 在個體中治療ｈｐｖ１６－陽性或ｈｐｖ１６－相關的癌症之方法
GB202108585D0 (en) 2021-06-16 2021-07-28 Rockend Ltd Methods and compositions
EP4377457A1 (fr) 2021-07-26 2024-06-05 Flagship Pioneering Innovations VI, LLC Compositions de trem et leurs utilisations
JP2024534428A (ja) 2021-09-17 2024-09-20 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー 環状ポリリボヌクレオチドを生成するための組成物及び方法
AU2022370530A1 (en) 2021-10-18 2024-05-02 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
KR20240122785A (ko) 2021-11-24 2024-08-13 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 면역원성 조성물 및 이의 용도
EP4436983A1 (fr) 2021-11-24 2024-10-02 Flagship Pioneering Innovations VI, LLC Compositions d'immunogènes du virus varicelle-zona et leurs utilisations
EP4436984A1 (fr) 2021-11-24 2024-10-02 Flagship Pioneering Innovations VI, LLC Compositions immunogènes de coronavirus et leurs utilisations
AU2022417517A1 (en) 2021-12-22 2024-06-27 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
WO2023122789A1 (fr) 2021-12-23 2023-06-29 Flagship Pioneering Innovations Vi, Llc Polyribonucléotides circulaires codant pour des polypeptides antifusogènes
WO2023164466A1 (fr) * 2022-02-23 2023-08-31 Sqz Biotechnologies Company Procédés de production de cellules gliales et leurs utilisations
WO2023220083A1 (fr) 2022-05-09 2023-11-16 Flagship Pioneering Innovations Vi, Llc Compositions de trem et procédés d'utilisation pour traiter des troubles prolifératifs
WO2023220729A2 (fr) 2022-05-13 2023-11-16 Flagship Pioneering Innovations Vii, Llc Compositions d'adn à double brin et procédés associés
WO2023230578A2 (fr) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions et procédés de modulation de facteurs de circulation
WO2023230549A2 (fr) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions et procédés de modulation de suppresseurs de tumeur et d'oncogènes
WO2023230573A2 (fr) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions et procédés de modulation de réponses immunitaires
WO2023230566A2 (fr) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions et procédés de modulation de cytokines
WO2023230570A2 (fr) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions et procédés de modulation de pilotes génétiques
WO2023240274A1 (fr) * 2022-06-10 2023-12-14 The Medical College Of Wisconsin, Inc. Induction d'une tolérance immunitaire pour des maladies auto-immunes par thérapie génique ciblant les plaquettes impliquant un polypeptide de glycoprotéine des oligodendrocytes de la myéline (mog)
WO2023250112A1 (fr) 2022-06-22 2023-12-28 Flagship Pioneering Innovations Vi, Llc Compositions de trem modifiées et leurs utilisations
CN115381950B (zh) * 2022-09-06 2023-08-18 天津医科大学总医院 Rab 35或其下游调控分子在治疗骨折后慢性疼痛中的应用
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024097664A1 (fr) 2022-10-31 2024-05-10 Flagship Pioneering Innovations Vi, Llc Compositions et procédés de purification de polyribonucléotides
WO2024102799A1 (fr) 2022-11-08 2024-05-16 Flagship Pioneering Innovations Vi, Llc Compositions et procédés de production de polyribonucléotides circulaires
WO2024129988A1 (fr) 2022-12-14 2024-06-20 Flagship Pioneering Innovations Vii, Llc Compositions et procédés d'administration d'agents thérapeutiques à un os
WO2024148139A2 (fr) * 2023-01-05 2024-07-11 Arizona Board Of Regents On Behalf Of Arizona State University Particules à base de métabolite et compositions associées pour prévenir et traiter des maladies et des troubles neurologiques
WO2024151673A2 (fr) 2023-01-09 2024-07-18 President And Fellows Of Harvard College Molécules d'acide nucléique recombinant et leur utilisation dans la cicatrisation de plaies
WO2024151685A1 (fr) 2023-01-09 2024-07-18 Beth Israel Deaconess Medical Center, Inc. Molécules d'acide nucléique recombinant et leur utilisation dans la cicatrisation des plaies
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
US20240293582A1 (en) 2023-02-17 2024-09-05 Flagship Pioneering Innovations Vii, Llc Dna compositions comprising modified cytosine
WO2024173828A1 (fr) 2023-02-17 2024-08-22 Flagship Pioneering Innovations Vii, Llc Compositions d'adn comprenant un uracile modifié
WO2024192420A1 (fr) 2023-03-15 2024-09-19 Flagship Pioneering Innovations Vi, Llc Compositions comprenant des polyribonucléotides et leurs utilisations
WO2024192422A1 (fr) 2023-03-15 2024-09-19 Flagship Pioneering Innovations Vi, Llc Compositions immunogènes et leurs utilisations
WO2024216128A1 (fr) 2023-04-12 2024-10-17 Flagship Pioneering Innovations Vi, Llc Trems destinés à être utilisés dans la correction de mutations faux-sens

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327710A (en) 1980-06-18 1982-05-04 The United States Of America As Represented By The Secretary Of Agriculture Process for encapsulating additives in resealed erythrocytes for disseminating chemicals via the circulatory system
IL86650A0 (en) 1987-06-30 1988-11-30 Biophor Corp Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane
US5258499A (en) 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
IT1245867B (it) 1991-06-03 1994-10-25 Consiglio Nazionale Ricerche Vaccini utilizzanti eritrociti come veicoli di antigeni
DE69127615T2 (de) 1991-06-14 1998-03-19 Europ Communities Transformierte Erythrozyten, Verfahren zu deren Herstellung, und ihre Verwendung in pharmazeutischen Zusammensetzungen
US5830462A (en) 1993-02-12 1998-11-03 President & Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5599705A (en) 1993-11-16 1997-02-04 Cameron; Robert B. In vitro method for producing differentiated universally compatible mature human blood cells
US6984379B1 (en) 1994-04-08 2006-01-10 Children's Hospital of LosAngeles Gene therapy by administration of genetically engineered CD34+ cells obtained from cord blood
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5648248A (en) 1994-12-30 1997-07-15 Boehringer Ingelheim International Gmbh Methods for producing differentiated cells from immature hematopoietic cells
US6060052A (en) 1995-10-30 2000-05-09 Systemix, Inc. Methods for use of Mpl ligands with primitive human hematopoietic stem cells
US6225290B1 (en) 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
TW520297B (en) 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
EP0932390A1 (fr) 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Composition de liposomes therapeutiques et procede
IL130035A0 (en) 1996-11-21 2000-02-29 New York Blood Ct Inc Method for conversion of blood type
DE69732225T2 (de) 1997-05-05 2005-06-23 Dideco S.R.L., Mirandola Verfahren zur Verkapselung von biologisch aktiven Stoffen in Erythrocyten und Gerät dafür
WO1999067360A2 (fr) 1998-06-25 1999-12-29 Hemosol Inc. Culture efficace de cellules souches permettant la production d'hemoglobine
US7767202B2 (en) 2001-03-16 2010-08-03 The Johns Hopkins University Modulation of systemic immune responses by transplantation of hematopoietic stem cells transduced with genes encoding antigens and antigen presenting cell regulatory molecules
US20030207247A1 (en) 2001-12-05 2003-11-06 Cerus Corporation Preparation of red blood cells having reduced immunogenicity
US20030133922A1 (en) * 2002-01-15 2003-07-17 Kasha John R. Oral tolerance using allogeneic platelets in ITP
WO2004029200A2 (fr) 2002-09-26 2004-04-08 Children's Medical Center Corporation Procede d'augmentation de la proliferation et/ou de la differentiation hematopoietique de cellules souches
AU2003298016A1 (en) 2002-11-27 2004-06-23 Regents Of The University Of Minnesota Homologous recombination in multipotent adult progenitor cells
JP4069730B2 (ja) 2002-11-27 2008-04-02 株式会社日立製作所 受信装置、印刷装置および印刷制御方法
ES2348868T3 (es) 2002-12-13 2010-12-16 Genetix Pharmaceuticals Inc. Vectores retrovirales terapeuticos para terapia genica.
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
WO2005118780A1 (fr) * 2004-06-04 2005-12-15 Universite Pierre Et Marie Curie - Paris Vi Methode de production de globules rouges
CA2574802A1 (fr) * 2004-07-20 2006-02-02 Isogenis, Inc. Inhibition specifique d'auto-immunite et maladies associees a des auto-antigenes
FR2873925B1 (fr) 2004-08-05 2006-10-13 Erytech Pharma Soc Par Actions Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes
DE102004054536A1 (de) 2004-11-06 2006-05-11 Capsulution Nanoscience Ag Multimodal veränderte Zellen als zellulare Darreichungsformen für aktive Substanzen und als diagnostische Zellpartikel
FR2884717B1 (fr) 2005-04-25 2009-07-03 Erytech Pharma Soc Par Actions Erythrocytes renfermant de l'arginine deiminase
WO2007039150A2 (fr) * 2005-09-23 2007-04-12 Cellerix, S.L. Populations de cellules presentant une activite immunoregulatrice, procede pour isoler ces populations de cellules, et leurs utilisations
FR2891843A1 (fr) 2005-10-06 2007-04-13 Erytech Pharma Soc Par Actions Erythrocytes contenant du 5-fluorouracile
US7462485B2 (en) * 2005-10-07 2008-12-09 Glaser Lawrence F Modified erythrocytes and uses thereof
US20070243137A1 (en) 2006-04-18 2007-10-18 Nanoprobes, Inc. Cell and sub-cell methods for imaging and therapy
US20100203024A1 (en) 2006-05-30 2010-08-12 Terman David S Sickled Erythrocytes, Nucleated Precursors & Erythroleukemia Cells for Targeted Delivery of Oncolytic Viruses, Anti-tumor Proteins, Plasmids, Toxins, Hemolysins & Chemotherapy
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
EP2012122A1 (fr) * 2007-07-06 2009-01-07 Medigene AG Protéines structurelles de parvovirus muté
FR2919804B1 (fr) 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
US7560263B2 (en) 2007-08-17 2009-07-14 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
US9260692B2 (en) 2007-10-31 2016-02-16 Universitat Zurich Use of modified cells for the treatment of multiple sclerosis
EP2057998A1 (fr) 2007-10-31 2009-05-13 Universitätsklinikum Hamburg-Eppendorf Utilisation de cellules modifiées dans le traitement de la sclérose en plaques
FR2925339B1 (fr) 2007-12-24 2010-03-05 Erytech Pharma Medicament pour le traitement du cancer du pancreas
EP2242507B1 (fr) 2008-02-13 2013-02-20 Erytech Pharma Formulation et procédé pour la prévention et le traitement de manifestation squelettique de la maladie de gaucher
FR2928270B1 (fr) 2008-03-10 2011-01-21 Erytech Pharma Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os
US8231895B2 (en) 2008-05-22 2012-07-31 Universidade De Coimbra Targeted delivery to human diseases and disorders
US20110092961A1 (en) * 2008-08-13 2011-04-21 Searete Llc Artificial cells
US8211656B2 (en) 2008-08-13 2012-07-03 The Invention Science Fund I, Llc Biological targeting compositions and methods of using the same
US20100040546A1 (en) 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
FR2938332B1 (fr) 2008-11-07 2011-11-25 Erytech Pharma Test predictif de la neutralisation de l'activite asparaginase
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
FR2944106B1 (fr) 2009-04-03 2012-09-28 Erytech Pharma Methode de dosage de l'inositol hexaphosphate (ihp).
US9834787B2 (en) 2009-04-09 2017-12-05 Sangamo Therapeutics, Inc. Targeted integration into stem cells
WO2010133298A1 (fr) 2009-05-19 2010-11-25 Eth Zurich Régulation de l'homéostasie de l'acide urique
CN102596208B (zh) 2009-10-27 2017-06-20 爱瑞泰克药物公司 用于诱导特异性免疫耐受的组合物
WO2011107409A1 (fr) 2010-03-02 2011-09-09 F. Hoffmann-La Roche Ag Vector d'expression
WO2011112883A1 (fr) 2010-03-12 2011-09-15 The Regents Of The University Of California Libération déclenchée de la cargaison de liposomes nanoparticulaires stabilisés
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CN101985634B (zh) * 2010-11-04 2012-06-13 中国人民解放军第四军医大学 一种gfp膜型表达的载体及转染该载体的阳性细胞的分选方法
CN102199199A (zh) * 2011-04-06 2011-09-28 中国人民解放军第四军医大学 膜定位葡萄球菌肠毒素a及其基因序列
AU2012326203B2 (en) 2011-10-17 2017-11-30 Massachusetts Institute Of Technology Intracellular delivery
AU2013220079B2 (en) 2012-02-15 2017-10-05 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
WO2013138314A1 (fr) 2012-03-13 2013-09-19 Anthrogenesis Corporation Cellules précurseurs d'érythrocyte modifiées et leurs utilisations
RU2667639C2 (ru) 2012-03-21 2018-09-21 Эритек Фарма Лекарственное средство для лечения острого миелоидного лейкоза (омл)
EP2669381A1 (fr) 2012-05-30 2013-12-04 AmVac AG Procédé pour l'expression de protéines hétérologues à l'aide d'un vecteur de virus recombinant à ARN négatifs comprenant une P proteine mutante
US8975072B2 (en) 2012-07-20 2015-03-10 Riken Human erythroid progenitor cell line comprising HPV E6/E7 operably linked to an inducible promoter and method for producing human enucleated red blood cells
EP2914274A4 (fr) 2012-11-01 2016-07-20 Sydney Children S Hospital Network Randwick And Westmead Probiotique modifié génétiquement pour le traitement de la phénylcétonurie
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
CN103224957B (zh) 2013-04-16 2017-08-04 福建三一造血技术有限公司 体外诱导生成含L‑ASPase II的红细胞药物的方法
FR3005420B1 (fr) 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
EP3546484B1 (fr) 2013-05-10 2021-09-08 Whitehead Institute for Biomedical Research Production in vitro de globules rouges avec des protéines sortaggables
WO2014183066A2 (fr) 2013-05-10 2014-11-13 Whitehead Institute For Biomedical Research Modification protéique de cellules vivantes à l'aide de sortase
PL2994117T3 (pl) 2013-05-10 2023-10-16 Erydel S.P.A. Sposób wytwarzania erytrocytów obciążonych jedną lub większą liczbą substancji będących przedmiotem zainteresowania pod względem farmaceutycznym oraz tak otrzymane erytrocyty
EP2813234A1 (fr) 2013-06-11 2014-12-17 Erytech Pharma Composition d'érythrocytes encapsulant phenylalanine hydroxylase et l'emploi thérapeutique
AU2014348683B2 (en) 2013-11-18 2020-11-05 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
FR3017299B1 (fr) 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
AU2015241422B2 (en) 2014-04-01 2020-12-03 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
SG10202003100XA (en) 2015-05-13 2020-05-28 Synlogic Operating Co Inc Bacteria Engineered to Reduce Hyperphenylalaninemia
US20180135012A1 (en) 2015-05-13 2018-05-17 Rubius Therapeutics, Inc. Membrane-receiver complex therapeutics
EP3187190A1 (fr) 2015-12-31 2017-07-05 Erytech Pharma Procédé de traitement d'un mammifère, y compris l'être humain, contre le cancer au moyen de la méthionine et la déplétion de l'asparagine
BR112018013728A2 (pt) 2016-01-11 2018-12-18 Rubius Therapeutics Inc composições e métodos relacionados a sistemas celulares terapêuticos multimodais para indicações imunitárias
BR112019000195A2 (pt) 2016-07-07 2019-04-24 Rubius Therapeutics, Inc. composições e métodos relacionados a sistemas celulares terapêuticos que expressam rna exógeno
WO2018102740A1 (fr) 2016-12-02 2018-06-07 Rubius Therapeutics, Inc. Compositions et méthodes se rapportant à des systèmes cellulaires destinés à pénétrer dans des tumeurs solides
MX2019009839A (es) 2017-02-17 2019-10-22 Rubius Therapeutics Inc Celulas eritroides funcionalizadas.
EP3672602A1 (fr) 2017-08-22 2020-07-01 Rubius Therapeutics, Inc. Procédés et compositions de nanoparticules lipidiques destinés à la production de cellules érythroïdes modifiées
US20190160102A1 (en) 2017-11-03 2019-05-30 Rubius Therapeutics, Inc. Compositions and methods related to therapeutic cell systems for tumor growth inhibition
US20190201548A1 (en) 2017-12-29 2019-07-04 Rubius Therapeutics, Inc. Gene editing and targeted transcriptional modulation for engineering erythroid cells
WO2019140116A2 (fr) 2018-01-10 2019-07-18 Rubius Therapeutics, Inc. Arn amplifiables pour systèmes cellulaires thérapeutiques

Also Published As

Publication number Publication date
HUE054471T2 (hu) 2021-09-28
IL285565B (en) 2022-04-01
US11576934B2 (en) 2023-02-14
JP2021102649A (ja) 2021-07-15
DK3125927T3 (da) 2021-04-19
JP2023052281A (ja) 2023-04-11
AU2015241422A1 (en) 2016-10-27
WO2015153102A1 (fr) 2015-10-08
US10869898B2 (en) 2020-12-22
AU2021232711A1 (en) 2021-10-14
JP6735233B2 (ja) 2020-08-05
CA2944492A1 (fr) 2015-10-08
RU2016142671A (ru) 2018-05-10
IL248143A0 (en) 2016-11-30
RU2020136119A (ru) 2021-05-17
US20180271910A1 (en) 2018-09-27
US20190247440A1 (en) 2019-08-15
KR20170005801A (ko) 2017-01-16
JP6865253B2 (ja) 2021-04-28
IL248143B (en) 2020-08-31
AU2019208203B2 (en) 2021-06-17
EP3583946A1 (fr) 2019-12-25
CN106456744A (zh) 2017-02-22
EP3125927A1 (fr) 2017-02-08
KR20220150986A (ko) 2022-11-11
US20170020926A1 (en) 2017-01-26
AU2019208203A1 (en) 2019-08-08
ES2865825T3 (es) 2021-10-18
BR112016022814A2 (pt) 2017-08-15
RU2736495C2 (ru) 2020-11-17
EP3125927B1 (fr) 2021-01-27
PL3125927T3 (pl) 2021-07-19
JP2019206573A (ja) 2019-12-05
PT3125927T (pt) 2021-04-30
MX2020000621A (es) 2020-11-12
IL285565A (en) 2021-09-30
US11554141B2 (en) 2023-01-17
BR112016022814A8 (pt) 2021-07-06
AU2015241422B2 (en) 2020-12-03
IL278643B (en) 2021-08-31
RU2016142671A3 (fr) 2018-11-01
JP2017517485A (ja) 2017-06-29
US20190388473A1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
MX2020000621A (es) Composiciones para usarse en inmunomodulacion.
PH12019500627A1 (en) Affinity-oligonucleotide conjugates and uses thereof
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
HK1245080A1 (zh) 自然殺傷細胞的方法和組合物
HK1243333A1 (zh) 用於修飾的t細胞的方法和組合物
IL251576A0 (en) Methods and compositions for creating or maintaining multifunctional cells
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
IL249828A0 (en) Limbal stem cells of cultured mammals, methods of their creation and uses thereof
TW201613966A (en) SynTac polypeptides and uses thereof
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
SG10201810150UA (en) Compositions and methods for enhanced gene expression in cone cells
EP3240552A4 (fr) Cellules tueuses naturelles et leurs utilisations
EP3215139A4 (fr) Compositions et procédés pour thérapies par cellules car-t améliorées
GB201611982D0 (en) Cell culture
EP3224349A4 (fr) Procédé de culture de cellules tueuses naturelles à l&#39;aide de lymphocytes t
EP3717631C0 (fr) Procédés de culture cellulaire
SG11201701237QA (en) Compositions for modulating cancer stem cells and uses therefor
EP3235900A4 (fr) Appareil de culture cellulaire
EP3198007A4 (fr) Méthodes et compositions pour moduler la fonction d&#39;un lymphocyte th-gm auxiliaire
HUE066922T2 (hu) Sejttenyésztési eljárások
PL3287521T3 (pl) Hodowla komórkowa
MX371121B (es) Composiciones para usarse en inmunomodulación.
GB201608764D0 (en) Novel cell culture
SG10202010002RA (en) Cell culture
IN2014MU03184A (fr)